Indomethacin Use in Pain Relief During Intrauterine Device Insertion
Overview
The aim of the investigators study is to test the analgesic effect of rectal indomethacin during Intrauterine device insertion.
Full Title of Study: “Rectal Indomethacin Use in Pain Relief During Intrauterine Device Insertion: A Randomized Controlled Trial”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Prevention
- Masking: Triple (Participant, Care Provider, Investigator)
- Study Primary Completion Date: July 2016
Interventions
- Drug: indomethacin suppositories
- The patients will be instructed to self-administer a single rectal dose of 50 mg indomethacin 30 min before the scheduled time of the procedure
- Drug: placebo
- The patient swill be instructed to self-administer a single rectal dose of placebo 30 min before the scheduled time of the procedure
Arms, Groups and Cohorts
- Experimental: indomethacin
- indomethacin suppositories
- Placebo Comparator: placebo
- placebo suppositories
Clinical Trial Outcome Measures
Primary Measures
- Mean pain score during IUD insertion
- Time Frame: intraoperative
Participating in This Clinical Trial
Inclusion Criteria
- Women not taken analgesics or anxiolytics in the 24 hours prior insertion – Women not taken misoprostol prior to intrauterine device insertion – Women who will accept to participate in the study Exclusion Criteria:
- Any contraindication to intrauterine device placement
Gender Eligibility: Female
Minimum Age: 20 Years
Maximum Age: 49 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Assiut University
- Provider of Information About this Clinical Study
- Principal Investigator: Ahmed Mohamed Abbas, Dr – Assiut University
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.